Regulatory Aspects of Connected and/or Continuous Downstream Processing – Lessons Learned

 

‌Bioprocess technologies for process intensification and continuous processing are available for essentially every step in a fully integrated bioprocessing platform. Last year, the first implementations in cGMP manufacturing environments were established for (partially) integrated continuous or intensified biomanufacturing processes. In this presentation, we will address some of the lessons learned during these implementations. In particular, we will focus on the regulatory expectations related to connected and/or continuous downstream processing unit operations.
 
These regulatory aspects include the challenges related to process development following the Quality by Design principles. Adequate development strategies will be discussed for critical unit operations and their translation into a control strategy in a fully integrated biomanufacturing platform will be reviewed. Other critical aspects in the regulatory framework relate to patient safety. In this context, particularly the strategies fro bioburden control and virus safety will be addressed.

Speaker

marc bisschops

Marc Bisschops

 

Director SLS - Integrated Process Solutions

Pall Biotech

Within Pall Biotech, Marc is responsible for all field support activities related to continuous bioprocessing. In addition to this, he is leading the development of the regulatory support initiative for continuous bioprocessing within Pall Biotech.

Biography

Regulatory Aspects of Connected and/or Continuous Downstream Processing – Lessons Learned

icon image

Find Out More About Single-Pass TFF

Download the application note to read a case study on how to save up to 30% of cost of goods per batch

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
May 2021
Overcome Exosome Production Challenges

Biotech | Pall Corporation webinar series

This webinar was recorded by BioPharma Asia and first published on their website. https://biopharma-asia.com. It is made available here by kind permission of BioPharma Asia and the presenters. Scroll down to see a transcript of the webinar question and answer session.

 

Hailed as the “next frontier” in cell therapy and regenerative medicine, exosomes are a type of extracellular vesicle and play a key role in the regulation of the intercellular communication processes.

David Haylock of VivaZome will present on upstream production of angiogenic exosomes using the iCELLis® nano fixed bed bioreactor. This will be followed by a presentation by Roberto Ciboldi of Pall Corporation on a platform solution including cell culture, purification and sterile filtration of exosomes.

Participants will be able to:

 

  • Compare the performance of the iCELLis Nano bioreactor to traditional flasks for exosome production from adherent cell culture
  • Understand how an integrated end to end platform delivers highly   purified and consistently-sized exosomes
  • Discover an innovative cGMP scalable manufacturing platform for   exosomes
Watch